Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538

Background: Adrenocortical carcinoma is a rare malignancy, with poor prognosis and limited treatment options for patients with advanced disease. Chemotherapy is the current standard first-line treatment, providing only a modest survival benefit. There is only limited treatment experience with immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Oliver, Senko, Clare, Carlino, Matteo S, Markman, Ben, Jackett, Louise, Gao, Bo, Lum, Caroline, Kee, Damien, Behren, Andreas, Palmer, Jodie, Cebon, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043165/
https://www.ncbi.nlm.nih.gov/pubmed/33889439
http://dx.doi.org/10.1080/2162402X.2021.1908771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043165/
https://www.ncbi.nlm.nih.gov/pubmed/33889439
http://dx.doi.org/10.1080/2162402X.2021.1908771

Ejemplares similares